@singingbones
I want to point out that there are no clinical trials studying HRT as the sole follow-up antiresorptive after any anabolic (Forteo/teriparatide, Tymlos/abaloparatide, or Evenity/romosozumab). That doesn't mean it can't work - it just means we're in uncharted territory and need to monitor closely so we don’t lose the precious gains.

The bone density (BMD) gained with Evenity tends to be lost at a faster rate after stopping compared to the gains from Forteo or Tymlos, if no antiresorptive follows, according to observational studies. This is because Evenity suppresses bone breakdown during treatment, and when it's stopped, bone breakdown (CTX) rebounds, sometimes even higher than it was before treatment started. Forteo and Tymlos don't cause this kind of rebound. This makes the choice and adequacy of the follow-up treatment after Evenity especially important.

Have you checked how your dose of estrogen gel compares to the doses typically associated with bone benefits? The most-studied dose for fracture prevention is equivalent to about a 50 mcg estradiol patch (or oral estradiol 1–2 mg). Lower doses could still help, but the evidence is strongest at standard doses. It may be worth discussing with your doctor whether a dose titration plan makes sense - or having a backup antiresorptive plan ready. I had one year worth of prescriptions written in advance to step up from 25 to 37.5 to 50 mcg patches if my bone markers or DXA suggest lower dose isn't enough.